Selank Dosage Chart
Intranasal protocol (250–500 mcg per nostril, 2–3× daily) and cycle length for the Russian-approved anxiolytic peptide.
Educational tool — not medical advice. This calculator provides estimates based on population averages and published trial data. Outputs are not clinical recommendations and do not replace evaluation by a qualified prescriber. Do not start, stop, or change a peptide therapy based on the result of this tool.
Selank is a synthetic analog of tuftsin developed at Russia's Institute of Molecular Genetics. It is Russian-approved as an anxiolytic with anti-asthenic and cognitive-supportive effects. Unlike benzodiazepines, it does not produce sedation, dependence, or withdrawal in published trial data. It is not FDA-approved in the US.
Selank at a Glance
| Typical dose | 250–500 mcg per nostril (total 500–1,000 mcg per dose) |
|---|---|
| Frequency | 2–3× per day intranasal |
| Cycle length | 2–4 weeks per cycle |
| Route | Intranasal spray |
| FDA status | Not FDA-approved (US). Russian-approved anxiolytic. |
| Source quality | Russian clinical trial data; limited Western validation. |
Selank Dosing by Use Case
Commonly cited protocols vary by what Selank is being used for. The table below summarizes typical ranges reported in clinical practice and published literature.
| Use case | Typical dose | Frequency | Cycle length | Notes |
|---|---|---|---|---|
| Anxiety / asthenic states | 500–1,000 mcg total per dose | 2–3× daily intranasal | 2–4 weeks | Standard Russian-protocol use case. Pulse-cycle rather than continuous use. |
| Cognitive support | 500 mcg total per dose | 2× daily intranasal | 2–3 weeks | Lower-dose protocol for memory and focus support. |
Stacking Selank
Selank is sometimes paired with Semax (another Russian-approved nasal peptide) for combined anxiolytic + nootropic effect. The two are typically alternated rather than co-administered to minimize receptor overlap.
Selank has a clean published safety profile in Russian trials but lacks Western validation.
- •Common side effects: minimal — mild nasal irritation is the most reported.
- •Does not produce sedation, dependence, or withdrawal in published trial data.
- •Long-term use beyond 4 weeks per cycle is not well-characterized.
- •Not FDA-approved.
- •Pregnancy or breastfeeding
- •Active sinusitis or nasal pathology (avoid intranasal route)
Selank Dosing FAQ
Selank produces anxiolytic effects without GABAergic sedation, dependence, or withdrawal — at least according to Russian trial data. It does not impair cognition or motor performance the way benzodiazepines can. Western validation is limited but the pharmacology is mechanistically distinct.
Acute anxiolytic effects are reported within hours to days of starting; the published Russian protocol is a 2–4 week course rather than a single dose.
Sources
Related Dosage Charts
Want the full Selank guide?
Mechanism, clinical evidence, side effects, costs, and provider listings for Selank therapy.
See Selank guideMedical Disclaimer: This content is for informational purposes only and should not be considered medical advice. Always consult with a qualified healthcare provider before beginning any peptide therapy treatment.